(Q35053191)

6 August 2017

1 reference

title

Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care (English)

1 reference

6 August 2017

1 reference

Jeffrey S Ross

1

1 reference

6 August 2017

Geoffrey S Ginsburg

series ordinal

2

1 reference

6 August 2017

publication date

1 August 2002

1 reference

6 August 2017

1 reference

6 August 2017

volume

7

1 reference

6 August 2017

issue

16

1 reference

6 August 2017

page(s)

859-864

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Molecular diagnostics: impact upon cancer detection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Molecular diagnostics: a powerful new component of the healthcare value chain.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

The present and future of molecular diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Commercial molecular diagnostics in the U.S.: The Human Genome Project to the clinical laboratory

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Clinical and Economic Impact of Adverse Drug Reactions in Hospitalized Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Personalized medicine: revolutionizing drug discovery and patient care

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Modern molecular diagnostics and the management of haematological malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Using genetic variation to study human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

1 reference

7 January 2021

Pharmacogenetics and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Quantitative monitoring of gene expression patterns with a complementary DNA microarray

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Gene expression analysis as an aid to the identification of drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Pharmacogenomics--teaching old drugs new tricks.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Using mRNA expression profiling to determine anticancer drug efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Transcriptional profiling in cancer: the path to clinical pharmacogenomics.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Discovery in toxicology: mediation by gene expression array technology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Analysis of genetic and epigenetic mechanisms of toxicity: potential roles of toxicogenomics and proteomics in toxicology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

HER2/neu as a predictive factor in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

STI571 (Gleevec) as a paradigm for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Mylotarg: antibody-targeted chemotherapy comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Early rheumatoid arthritis: can we predict its outcome?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Noninvasive surrogate markers of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Laboratory surrogates for anti-atherosclerotic drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Molecular diagnostics in monogenic and multifactorial forms of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

New molecular tools for efficient screening of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Molecular diagnostics of infectious diseases: state of the technology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Molecular diagnostics for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Technical aspects of minimal residual disease detection in carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Applications of proteomics in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Proteomics: a technology-driven and technology-limited discovery science

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Cancer proteomics: the state of the art

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

Use of proteomic patterns in serum to identify ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902405-4

7 January 2021

10.1016/S1359-6446(02)02405-4

Identifiers

DOI

1 reference

6 August 2017

1 reference